ELEV
Elevation Oncology
ELEV
ELEV
Delisted
ELEV was delisted on the 22nd of July, 2025.
32 hedge funds and large institutions have $13.9M invested in Elevation Oncology in 2023 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 8 increasing their positions, 7 reducing their positions, and 10 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
less ownership
Funds ownership: →
less funds holding
Funds holding: →
less capital invested
Capital invested by funds: $ → $
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
90% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 10
Holders
32
Holding in Top 10
2
Calls
–
Puts
–
Top Buyers
| 1 | +$237K | |
| 2 | +$54.5K | |
| 3 | +$23.2K | |
| 4 |
Two Sigma Advisers
New York
|
+$13.9K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$2.1K |
Top Sellers
| 1 | -$662K | |
| 2 | -$497K | |
| 3 | -$178K | |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$134K |
| 5 |
Walleye Capital
New York
|
-$98.7K |